Prevalence and Independent Risk Factors for Erectile Dysfunction in Spain: Results of the Epidemiologia De La Disfuncion Erectil Masculina Study

Martín‐Morales, Antonio; Sánchez-Cruz, José Juan; Tejada, Iñigo Sáenz de; Rodríguez-Vela, L.; Jiménez-Cruz, J.F.; Burgos-Rodriguez, R.

doi:10.1016/s0022-5347(05)65986-1

Cited by 483 publications

(323 citation statements)

References 16 publications

Supporting

Mentioning

270

Contrasting

Unclassified

Order By: Relevance

“…All of these conditions contribute to erectile dysfunction, and in men with diabetes, the risk of erectile dysfunction is approximately four-fold higher than in men without diabetes [2,3]. Erectile dysfunction in men with diabetes is also more severe and less responsive to therapy than in men without diabetes [4].…”

Section: Introductionmentioning

confidence: 99%

Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials

et al. 2004

View full text Add to dashboard Cite

Aims/hypothesis. A retrospective analysis of pooled data from twelve placebo-controlled trials was conducted to characterise the efficacy and safety of tadalafil for the treatment of erectile dysfunction in men with diabetes compared with that in men without diabetes. Methods. Patients were randomly allocated to tadalafil 10 mg, 20 mg, or placebo, taken as needed for 12 weeks. The study population comprised 637 men with diabetes (mean age 57 years) and 1681 men without diabetes (mean age 56 years). Results. At baseline, patients with diabetes had more severe erectile dysfunction than patients without diabetes, with mean International Index of Erectile Function (IIEF) erectile function domain scores of 12.6 and 15.0 respectively (p<0.001). Compared with placebo, tadalafil 10 mg and 20 mg improved all primary efficacy outcomes in both patient groups (p<0.001). Men with diabetes receiving tadalafil 20 mg experienced a mean improvement of 7.4 in their IIEF erectile function domain score against baseline versus 0.9 for placebo (p<0.001). This group reported on average that 53% of their attempts at intercourse were successful, compared with 22% for placebo (p<0.001 for the change from baseline). Baseline IIEF erectile function domain scores correlated inversely with baseline HbA 1 c levels. The responses to tadalafil were similar regardless of levels of baseline glycaemic control, diabetic therapy received, or previous use of sildenafil. Conclusions/interpretation. Despite more severe baseline erectile dysfunction in men with diabetes, tadalafil was efficacious and well tolerated in this population. As reported for other phosphodiesterase 5 inhibitors, the response to tadalafil was slightly lower in men with diabetes than in men without diabetes.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Lukacs et al 11 surveyed a cohort of 6000 males with LUTS and found that a patient's sexual dysfunction was related to both age and LUTS severity. In a cohort of 2476 Spanish men, Martin-Morales et al 12 found that the prevalence of ED increased from 8.5% in men 35-39 years old to 48% in men 60-70 years old, as assessed by the International Index of Erectile Function (IIEF). Furthermore, LUTS was found to be the strongest independent risk factor for ED, with an age-adjusted odds ratio (95% confidence interval) of 2.67 (1.48-4.80).…”

Section: Introductionmentioning

confidence: 99%

PDE5 inhibitors for LUTS

Mouli

McVary

2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

To review the current literature regarding the relationship between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED), and the role of phosphodiesterase-5 (PDE5) inhibitors for the treatment of LUTS. Review of recently published (1990)(1991)(1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009) Keywords: erectile dysfunction; benign prostatic hyperplasia; lower urinary tract symptoms; LUTS; ED IntroductionLower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are highly prevalent in aging males, with a substantial impact on quality of life (QOL). Multiple studies have shown a strong association between these two entities, independent of other risk factors. This relationship may be explained by four interrelated theories: the nitric oxide/cyclic guanosine monophosphate pathway (NO/cGMP), the Rho-kinase pathway, autonomic hyperactivity (AH), and pelvic atherosclerosis. Clinical trials have shown that phosphodiesterase-5 (PDE5)-inhibitor treatment results in significant improvement in LUTS. The exact mechanism of action is not well understood. The results of these studies indicate that PDE5-inhibitor treatment has a role in treating LUTS in the setting of ED. Furthermore, PDE5-inhibitor therapy may expand to treat not only men with ED and/or LUTS, but also LUTS in women.

show abstract

“…6 According to the EDEM (Epidemiologia de la Disfuncion Erectil Masulina) study, subjects with prostatic disease have a 2.9 and 2.7 times higher probability (OR) of developing ED than male subjects from the general population as measured by a Single Assessment Question and the Erectile Function Domain of the International Index of Erectile Function (IIEF), respectively. 7 Furthermore, the EDEM study detected and quantified a strong association between lower urinary tract symptoms, measured with the International Prostate Symptom Score (IPSS), and the likelihood of developing ED, measured with the Erectile Function Domain of the IIEF. 8 Taking subjects aged between 25 and 39 years with mild symptoms on the IPSS as a reference category, the risk of developing ED increases more than two-fold if urinary symptoms are moderate and more than three-fold if symptoms are severe in any of the age groups (Table 1).…”

Section: Introductionmentioning

confidence: 99%

Specific aspects of erectile function in urology/andrology

et al. 2004

View full text Add to dashboard Cite

The urologist/andrologist is the specialist responsible for diagnosis and treatment of health problems related to the genitourinary tract, and his or her participation in comprehensive care for a patient with erectile dysfunction (ED) is fundamental and often indispensable. The urologists/ andrologists should characterize the origin of ED because of their knowledge and familiarity of all diagnostic tests and second-and third-line therapy. The origin of ED is important to determine for various reasons, such as young people suitable for etiologic treatment, medicolegal reasons, or patients' wishes for a better understanding of their condition. A review of the diagnostic tests available as well as indications for second-and third-line therapy is presented. The close relationship between ED and urological disorders, such as benign prostatic hyperplasia, prostate cancer and their treatments, and renal failure, in association with penile conditions like Peyronie's disease, priapism, and possible androgen deficiency in men older than 50 years, places the urologist at the center of integrated treatment of male ED.

show abstract

Prevalence and Independent Risk Factors for Erectile Dysfunction in Spain: Results of the Epidemiologia De La Disfuncion Erectil Masculina Study

Cited by 483 publications

References 16 publications

Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials

Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials

PDE5 inhibitors for LUTS

Specific aspects of erectile function in urology/andrology

Contact Info

Product

Resources

About